Gastroenterology and Hepatology From Bed to Bench最新文献

{"title":"The link between gluten intake and the risk of cancers.","authors":"Sajjad Bakhtiari, Nastaran Asri, Sepehr Maleki, Saba Rahimi, Amirreza Jabbari, Alireza Ahmadzadeh, Somayeh Jahani-Sherafat, Masoumeh Farahani, Ehsan Nazemalhosseini Mojarad, Mohammad Rostami-Nejad","doi":"10.22037/ghfbb.v17i2.2945","DOIUrl":"10.22037/ghfbb.v17i2.2945","url":null,"abstract":"<p><p>Gluten is a complex mixture of hundreds of related proteins, with the two major groups being gliadin and glutenin. Gliadin primarily affects the viscosity of dough, while glutenin contributes to its strength. Nowadays, there is evidence suggesting an increase in gluten exposure due to advancements in cereal technology. Consumption of gluten can lead to development of gluten-related disorders (GRDs) in susceptible individuals. Some GRDs have been strongly associated with an increased risk of developing certain types of cancer. Colorectal cancer and lymphoma are among the most commonly reported malignancies associated with GRDs. Dietary factors, including gluten intake, have been recognized as significant modifiable risk factors for the development of digestive system cancers. The present study aimed to collect current information on the effect of gluten on the incidence of cancer in the general population and among GRDs patients. Protein-Protein Interaction (PPI) Network analysis of common genes between celiac disease (CD) and cancer was also conducted.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"17 2","pages":"132-139"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11234494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation strategy of anti-mitochondrial antibodies M2-negative: the role of multiplex rodent tissues and related clinical implications.","authors":"Chiara Tolassi, Roberto Assandri","doi":"10.22037/ghfbb.v17i1.2879","DOIUrl":"10.22037/ghfbb.v17i1.2879","url":null,"abstract":"<p><p>Indirect immunofluorescence on HEp-2 cell line (HEp-2-IIF) remains \"gold standard\" method for the detection of antinuclear antibodies (ANA). ANA is an operative definition, showing the possibility of autoantibodies (Aab) to bind nuclear, and cytoplasmic antigens. One of the major examples is represented by anti-mitochondrial antibodies (AMAs), which target proteins of the inner and outer mitochondrial membranes, located into the cytoplasm. The standard IIF on rat kidney/stomach/liver tissue sections, with the combined use of other commercial assays, may all be used in ordinary lab life to validate the AC-21 pattern on Hep-2 cells. The routine lab experience teaches that commercial kits cannot always be detected and define specific AMAs. In these cases the literature proposes the use of other homemade assays to detect AMAs as immunoprecipitation (IP) and Western blot (IP-WB). However, using IP or IP-WB is difficult to apply in a routine laboratory, because of numerous cases to process and the related troubles. Where find confirmation of the AC-21 pattern if line-immunoblot and other routine methods (ELISA, CLIA/FEIA assays) fail? We review AC-21 AMA-like sera from our patients (year 2022) and propose a revised diagnostic algorithm based on the combined use of IIF on Hep-2 cells, line immunoblot and IIF on rodent tissue as a third line method. We demonstrated that, particularly in cases where the second level test was unsuccessful, the application of IFI on rodent tissues became indispensable to verify the existence of AMAs.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"17 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11080696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abdominal pain in a young lady with inverted Meckel's diverticulum: a case report.","authors":"Seyed Mohammad Reza Nejatollahi, Keihan Mostafavi, Fariba Ghorbani","doi":"10.22037/ghfbb.v17i1.2815","DOIUrl":"10.22037/ghfbb.v17i1.2815","url":null,"abstract":"<p><p>Meckel diverticulum is the most common congenital anomaly of the gastrointestinal tract which is located in small bowel within 2 feet of the ileocecal valve. Nevertheless, an inverted Meckel's diverticulum is an uncommon condition believed to result from aberrant peristalsis in that specific area. This article showed signs, symptoms, and possible clinical presentations using CARE guidelines in a case of inverted Meckel's diverticulum and reviews other possible features lastly, definitive treatment, results, and case follow-up were shown to refresh, and raise surgeons' awareness of this rare disorder.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"17 1","pages":"100-103"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11080686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140913696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and development of a self-care application for patients with liver cirrhosis.","authors":"Zahra Asadzadeh, Elham Maserat, Leila Alizadeh, Zeinab Mohammadzadeh","doi":"10.22037/ghfbb.v17i1.2846","DOIUrl":"10.22037/ghfbb.v17i1.2846","url":null,"abstract":"<p><strong>Aim: </strong>Due to the capabilities of the mobile application in the self-care of patients, the present study was conducted to design and evaluate a mobile-based self-care application for patients with liver cirrhosis.</p><p><strong>Background: </strong>Liver cirrhosis is a progressive and chronic disease that, if left untreated, leads to liver cancer and, finally, the death of the patient.</p><p><strong>Methods: </strong>This study was conducted in six phases, including determining and confirming the validity of the minimum data set and capabilities for the application, designing a conceptual and logical model and determining the technical capabilities, designing the application, evaluating the prototype usability in a laboratory environment by technical experts, evaluation of the application usability in a real environment by 30 patients with QUIS (Questionnaire of User Interface Satisfaction) questionnaire.</p><p><strong>Results: </strong>The designed application has capabilities such as calculating the patient's MELD score (Model for End-Stage Liver Disease), medication reminder, location in emergency, and conversation with the physician. The results showed that the patients evaluated the application with a score of 7.94 (out of 9 points) at a good level.</p><p><strong>Conclusion: </strong>The self-care application can help patients with liver cirrhosis and their families access the necessary information related to the special care of the patient at any time and place; it also helps better manage the patient's life, improve the quality of life, and monitor the patient. These applications can effectively manage chronic diseases by reducing the burden of referrals and costs.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"17 1","pages":"74-86"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11080697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of <i>GNB1</i> derivative circular RNAs <i>hsa_circ_0009361</i> and <i>hsa_circ_0009362</i> expressions in colorectal cancer patients: potential new diagnostic factors.","authors":"Zahra Mozooni, Nafiseh Golestani, Hossein Sadeghi","doi":"10.22037/ghfbb.v17i1.2863","DOIUrl":"10.22037/ghfbb.v17i1.2863","url":null,"abstract":"<p><strong>Aim: </strong>We aim to investigate the relationship between <i>hsa_circ_0009361</i> plus <i>hsa_circ_0009362</i> expression levels and the clinicopathological features of colorectal cancer (CRC) patients.</p><p><strong>Background: </strong>Circular RNAs (circRNAs) are implicated in the progression and development of CRC. CircRNAs have been recognized as diagnostic and prognostic biomarkers, opening up a new window to comprehend the molecular basis of CRC. Given the significance of circRNAs and the G protein subunit b1 (<i>GNB1</i>) gene in malignancies, the goal of the current investigation was to determine the expression levels of <i>GNB1</i> derivative circular RNAs circGNB1 (<i>hsa_circ_0009361</i> and <i>hsa_circ_0009362</i>) in CRC and adjacent control tissues.</p><p><strong>Methods: </strong>The expression levels of the <i>GNB1</i> derivative circular RNAs (<i>hsa_circ_0009361</i> and <i>hsa_circ_0009362</i>) were evaluated using the quantitative real-time PCR (qRT-PCR) method in 45 CRC tissues and adjacent control tissues. Furthermore, we analyzed the diagnostic power of the mentioned circRNAs by plotting the receiver operating characteristic (ROC) curve. The association between the expression levels of <i>hsa_circ_0009361</i> and <i>hsa_circ_0009362</i> was evaluated using correlation analysis.</p><p><strong>Results: </strong>Our results revealed that the expression levels of <i>hsa_circ_0009361</i> and <i>hsa_circ_0009362</i> were significantly down-regulated in CRC tissues compared to the adjacent control group. Analysis of patients' clinicopathological features indicated that expressions of <i>hsa_circ_0009361</i> and <i>hsa_circ_0009362</i> were differently related to lymph vascular invasion (P<0.001). ROC curve results showed that these circRNAs are good candidate diagnostic biomarkers in CRCs. Pearson's correlation test revealed a positive correlation between <i>hsa_circ_0009361</i> and <i>hsa_circ_0009362</i> expression levels (P<0.0001).</p><p><strong>Conclusion: </strong>These results demonstrated that <i>hsa_circ_0009361</i> and <i>hsa_circ_0009362</i> expression levels may be used as possible diagnostic biomarkers for CRC.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"17 1","pages":"37-44"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11080687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of stool color card as screening tool for biliary atresia in resource-constraint country.","authors":"Rubaiyat Alam, Khan Lamia Nahid, Md Omar Faruk, Elena Haque Rasna, Md Rukunuzzaman","doi":"10.22037/ghfbb.v17i2.2931","DOIUrl":"10.22037/ghfbb.v17i2.2931","url":null,"abstract":"<p><strong>Aim: </strong>The study was aimed to find out the efficacy of a stool color card (SCC) in differentiating biliary atresia (BA) from non-BA in resource-limited countries.</p><p><strong>Background: </strong>stool color screening system was introduced in 2004 which lead to marked improvement in sensitivity of detecting BA.</p><p><strong>Methods: </strong>This cross-sectional observational study was conducted from January, 2019 through July, 2022 on purposively sampled infants who developed jaundice before three months of age, had direct bilirubin of > 20 % of total with pale stool and dark urine.</p><p><strong>Results: </strong>144 cases (male, 96) were included in the study and their mean age at admission was 87.3±37.2 days and mean age at onset of jaundice was 6.1±7.7 days. BA was confirmed in 106 (73.6%) cases and 38 (26.4%) children were in non-BA group. Frequency of persistent pale stool between BA and non- BA were 88 vs 8 (83.0 % Vs 21.0 %) which was highly significant (p=0.000). Mean difference of total and direct serum bilirubin, median alanine transferase and alkaline phosphatase were not statistically significant between two groups. Median of serum gamma glutamyl transpeptidase (GGT) in BA was 570 U/L and in non-BA it was 138.0 U/L which was statistically significant (p=0.000). The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of SCC were 83%, 78.9%, 91.7%, 62.5% and 81.9% respectively.</p><p><strong>Conclusion: </strong>SCC has good sensitivity to diagnose BA but failed to prove better specificity to rely simply on it. SCC may be used as early screening tool for prompt referral to appropriate medical care centers for final evaluation of BA.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"17 2","pages":"146-150"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11234486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"All-cause mortality of hospitalized inflammatory bowel disease patients: a multicenter study from Iran.","authors":"Sulmaz Ghahramani, Babak Tamizifar, Vahid Rajabpour, Seyedeh-Zeynab Hosseinian, Samira Saeian, Hassan Shahoon, Kamran Bagheri Lankarani","doi":"10.22037/ghfbb.v17i3.2962","DOIUrl":"10.22037/ghfbb.v17i3.2962","url":null,"abstract":"<p><strong>Aim: </strong>In this multicenter study, we investigated all causes of mortality in hospitalized inflammatory bowel disease (IBD) patients.</p><p><strong>Background: </strong>The widespread use of biologics and immune suppressive treatments, along with the longer lifespan of patients with IBD, may have changed the cause of death in this population. Knowing this may lead to better preventive and therapeutic strategies for IBD patients.</p><p><strong>Methods: </strong>This cross-sectional study reviewed records of 1926 IBD patients hospitalized in referral hospitals in Isfahan and Shiraz during 2013-2021. In nine years, 84 patients, 39 from Isfahan and 45 from Shiraz, died. We retrospectively gathered data on demographic, clinical, and laboratory information, as well as the cause of death. We extracted the cause of death from the death sheets and classified it using the International Classification of Diseases (ICD-10). Using the Kaplan-Meier model, we estimated the median survival time from disease diagnosis to death.</p><p><strong>Results: </strong>Males accounted for 47 (55%) of the deceased patients. The mean age of the patients was 48.63 ± 18.7 years. The mortality rates among hospitalized UC and CD patients were 7.2% and 7.8%, respectively. The median duration of admission to death was 8 days, with 19 (22.6%) of IBD patients dying on the first day of their hospital admission. Half of the cohort of deceased IBD patients had survived for 8 years following their disease diagnosis. 32.7% of all recorded causes of death were due to certain infectious diseases. The second and third most common causes of death were diseases of the digestive system and diseases of the circulatory system, including pulmonary embolism, accounting for 30.1% and 14.2%, respectively.</p><p><strong>Conclusion: </strong>According to this study from Iran, infectious diseases are the leading cause of death among hospitalized IBD patients. Prevention and clinical management of pulmonary embolism in IBD patients require more careful consideration. We strongly encourage population-based cohort studies to enhance the findings.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"17 3","pages":"279-287"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in blood DNA methylation-based assay for colorectal cancer early detection: a systematic updated review.","authors":"Milad Khabbazpour, Masoud Tat, Ashraf Karbasi, Mohammad Ali Abyazi, Ghazal Khodadoustan, Zohreh Heidary, Majid Zaki-Dizaji","doi":"10.22037/ghfbb.v17i3.2978","DOIUrl":"10.22037/ghfbb.v17i3.2978","url":null,"abstract":"<p><strong>Aim: </strong>A systematic review was conducted to summarize the methylated circulating tumor DNA (ctDNA) markers reported over the last decade for early detection of colorectal cancer (CRC) and to identify the main technical challenges that are impeding their clinical implementation.</p><p><strong>Background: </strong>CRC is a major cause of cancer deaths worldwide, but early detection is key for successful treatment. Non-invasive methods such as methylated ctDNA testing show promise for improving detection and monitoring of CRC.</p><p><strong>Methods: </strong>A comprehensive search was performed using Web of Science, PubMed, and Scopus up to December 30, 2023, limited to articles published in the last 10 years (after 2012), while including advanced adenoma/stage 0 or stage I/II samples in biomarker validation.</p><p><strong>Results: </strong>After identifying 694 articles, removing duplicates and screening titles, abstracts, and full texts, a total of 62 articles were found to meet the inclusion criteria. Among the single biomarkers, MYO1-G, SEPT9, SDC2, and JAM3 revealed the highest sensitivity for polyps and stage I/II CRC. For multi-biomarkers with suitable sensitivity, combinations of SFRP1, SFRP2, SDC2, PRIMA1, or ALX4, BMP3, NPTX2, RARB, SDC2, SEPT9, VIM or ZFHX4, ZNF334, ELOVL2, UNC5C, LOC146880, SFMBT2, GFRA1 were identified for polyps and stage I/II CRC.</p><p><strong>Conclusion: </strong>Enhancing sensitivity and specificity of molecular screening methods is crucial for improving CRC detection. Identifying a select few valuable biomarkers is key to reducing costs, despite challenges posed by low ctDNA levels in plasma, particularly in early-stage cancers.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"17 3","pages":"225-240"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic thiol/disulfide homeostasis and myeloperoxidase levels in Gilbert's syndrome with mild hyperbilirubinemia.","authors":"Burak Furkan Demir, Canan Topcuoglu, Turan Turhan, Emin Altıparmak, Nisbet Yılmaz, İhsan Ateş","doi":"10.22037/ghfbb.v17i3.2968","DOIUrl":"10.22037/ghfbb.v17i3.2968","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to compare dynamic thiol/disulfide homeostasis and myeloperoxidase (MPO) levels in patients with Gilbert's syndrome (GS) and healthy controls.</p><p><strong>Background: </strong>Thiol/disulfide homeostasis and MPO levels are both associated with increased progression of atherosclerosis.</p><p><strong>Methods: </strong>The study included a total of 130 voluntary participants comprising 65 patients with GS and 65 healthy controls. These patients were selected randomly and dynamic thiol/disulfide homeostasis, MPO, complete blood count results, and biochemistry and lipid parameters were evaluated. Patients with known chronic diseases, medication usage, and acute infections were excluded from the study. Serum total thiol and native thiol levels were measured using the fully automated colorimetric method, while serum MPO levels were measured using the sandwich ELISA method.</p><p><strong>Results: </strong>We found that patients with GS had significantly higher total thiol (352.3±38.6 vs. 317.9±47.9, p<0.001) and native thiol (386.6±42.6 vs. 348.0±51.1, p<0.001) and significantly lower disulfide (15.7±4.0 vs. 17.3±4.0, p=0.022) and MPO (130.7 vs. 166.3, p=0.006). In patients with bilirubin of <1 mg/dL, total thiol and native thiol levels were lower and disulfide, disulfide/native thiol (DNT) and disulfide/total thiol (DTT) ratios, and MPO levels were higher. Patients with bilirubin of <1 mg/dL also had higher total cholesterol.</p><p><strong>Conclusion: </strong>In these patients with GS, the thiol/disulfide balance shifted towards thiols and proinflammatory MPO levels were lower. When bilirubin was <1 mg/dL, disulfide, DNT and DTT ratios, and MPO were higher. Bilirubin levels affected all parameters of thiol/disulfide homeostasis and MPO levels independently of other risk factors. In light of our results, we suggest that mild hyperbilirubinemia in cases of GS has an anti-inflammatory and antioxidant effect and may be protective against atherosclerosis.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"17 3","pages":"270-278"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opium use and gastrointestinal cancers: a systematic review and meta-analysis study.","authors":"Mahsa Mohammadi, Philippe Tadger, Amir Sadeghi, Niloufar Salehi, Mohsen Rajabnia, Elham Paraandavaji, Sasan Shafiei, Ahmad Pirani, Mohammad Reza Hatamnejad, Erfan Taherifard, Fatemeh Kheshti, Arman Naderilordejani, Forough Honarfar, Khaled Rahmani, Majid Soruri, Hamed Kord Varkaneh, Omid Dadras, Ali Jahanian, Sara Rasta, Mohammad Reza Zali","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Aim: </strong>The current systematic review and meta-analysis aimed to assess the association between Gastrointestinal (GI) cancers and opium use.</p><p><strong>Background: </strong>GI malignancies are a global public health issue and are associated with many risk factors including genetic and lifestyle factors.</p><p><strong>Methods: </strong>PubMed, Web of Science, Embase and Scopus and the Google Scholar search engine in addition to Persian databases including Magiran and SID were searched using relevant keywords. The associations of opium use, long duration of opium use, high daily amount opium use and high cumulative opium use and GI cancer and various subtypes of GI cancers were estimated and pooled in format of odds ratios (OR) and their corresponding 95% confidence intervals (CI) with a random effects model.</p><p><strong>Results: </strong>22 articles that were published between 1983 and 2022 entered the analyses. There were significant relationships between opium use based on crude effect sizes (OR: 2.53, 1.95-3.29) and adjusted effect sizes (OR: 2.64, 1.99-3.51), high daily opium use (or: 3.41, 1.92-6.06), long duration of opium use (OR: 3.03, 1.90-4.84) and high cumulative opium use (OR: 3.88, 2.35-6.41), all compared to never opium use, and GI cancer. The results were not sensitive to sensitivity analyses and no influential publication biases were found in these analyses.</p><p><strong>Conclusion: </strong>Our meta-analysis showed that opium use could be associated with increased risk of overall and some particular GI cancers including oropharyngeal, gastric, pancreatic and colorectal cancers. Opium use as a potentially modifiable factor, therefore, should be more emphasized.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"17 2","pages":"104-120"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11234493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}